Sino Biopharm partners with Sciwind on IL-29 project

Sino Biopharmaceutical (HKEX:1177) has announced an exclusive strategic cooperation agreement with Sciwind Biosciences to license and develop the human interleukin-29 (IL-29) project, also known as interferon λ 1, in 19 countries, including China, Brazil, Saudi Arabia, and Singapore. Sciwind's IL-29 project, internally designated as CPX102 by Sino Biopharm, is a nebulized inhalation solution optimized by protein engineering and currently in Phase IIb clinical trials in China for treating respiratory syncytial virus (RSV) infection in children. The company noted that CPX102 is the only National Class 1 innovative drug for the treatment of RSV through nebulization to have entered clinical trials stage in China. Sino Biopharm believes CPX102 has the potential to become a blockbuster product in the respiratory/anti-infection space.